RickyKHsuMD

PubMed

• 2 citations
  Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes.
  Ricky K Hsu, Jennifer S Fusco, Cassidy E Henegar, Vani Vannappagari, Andrew Clark, Laurence Brunet, Philip C Lackey, Gerald Pierone Jr, Gregory P Fusco> ;BMC Infectious Diseases. 2023 Feb 13
• Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV.
  Ricky K Hsu, Laurence Brunet, Jennifer S Fusco, Karam Mounzer, Joyce C Lamori, Gregory P Fusco> ;AIDS Research and Human Retroviruses. 2022 Oct 1
• 6 citations
  Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort.
  Karam Mounzer, Jennifer S Fusco, Ricky Hsu, Laurence Brunet, Vani Vannappagari, Kevin R. Frost, Mark S. Shaefer, Alex R. Rinehart, Keith M Rawlings, Gregory Fusco> ;AIDS Patient Care and Stds. 2021 Oct 4
• 5 citations
  To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment.
  Karam Mounzer, Laurence Brunet, Christina M. Wyatt, Jennifer S Fusco, Vani Vannappagari, Allan R Tenorio, Mark S. Shaefer, Leigh Ragone, Ricky Hsu, Gregory Fusco> ;AIDS. 2021 Jul 1
• 5 citations
  Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United Sta...
  Karam Mounzer, Laurence Brunet, Ricky Hsu, Jennifer S Fusco, Vani Vannappagari, Cassidy Henegar, Jean van Wyk, Melissa Crawford, Janet Lo, Gregory Fusco> ;AIDS Research and Human Retroviruses. 2021 Jun 17
• 67 citations
  Weight gain before and after switch from TDF to TAF in a U.S. cohort study
  Patrick W. G. Mallon, Laurence Brunet, Ricky Hsu, Jennifer S Fusco, Karam Mounzer, Girish Prajapati, Andrew P Beyer, Michael Wohlfeiler, Gregory Fusco> ;Journal of the International AIDS Society. 2021 Apr 1
• 7 citations
  Incident type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs
  Ricky Hsu, Laurence Brunet, Jennifer S Fusco, Karam Mounzer, Vani Vannappagari, Cassidy Henegar, Jean van Wyk, Lloyd Curtis, Janet Lo, Gregory Fusco> ;AIDS. 2021 Jan 1
• 1 citations
  Antiretroviral therapy and liver disorders in the OPERA® cohort.
  Michael Wohlfeiler, Karam Mounzer, Laurence Brunet, Jennifer S Fusco, Vani Vannappagari, Lloyd Curtis, Nassrin Payvandi, Michael Aboud, Ricky Hsu, Philip Lackey, Grego...> ;Therapeutic Advances in Drug Safety. 2020 Dec 8
• 5 citations
  Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score.
  R Hsu, Laurence Brunet, Jennifer S Fusco, Andrew P Beyer, Girish Prajapati, Christina M. Wyatt, Michael Wohlfeiler, Gregory Fusco> ;HIV Medicine. 2021 May 1
• 4 citations
  Assessing bias introduced in estimated glomerular filtration rate (eGFR) by the inhibition of creatinine tubular secretion from common antiretrovirals
  Laurence Brunet, Christina M. Wyatt, R Hsu, Karam Mounzer, Jennifer S Fusco, Gregory Fusco> ;Antiviral Therapy. 2020 Nov 19
• 5 citations
  Validation of the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) chronic kidney disease risk score in HIV‐infected patients in the USA
  Anthony Mills, Kathy Schulman, Jennifer S Fusco, Laurence Brunet, R Hsu, Andrew P Beyer, Girish Prajapati, Karam Mounzer, Gregory Fusco> ;HIV Medicine. 2020 Jan 27
• 29 citations
  HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study
  Karam Mounzer, R Hsu, Jennifer S Fusco, Laurence Brunet, Cassidy Henegar, Vani Vannappagari, Chris M. Stainsby, Mark S. Shaefer, Leigh Ragone, Gregory Fusco> ;AIDS Research and Therapy. 2019 Jan 16
• 13 citations
  Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA‐B*5701 Screening as a Risk‐Mitigation Measure
  C. Stainsby, Teodora Perger, Vani Vannappagari, Karam Mounzer, Ricky Hsu, Cassidy Henegar, James Oyee, Rimgaile Urbaityte, Charlotte E. Lane, Lindsay M. Carter, Gary E...> ;Pharmacotherapy. 2019 Jan 1
• 7 citations
  Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database.
  Ricky Hsu, Jennifer S Fusco, Cassidy Henegar, Karam Mounzer, Michael Wohlfeiler, Vani Vannappagari, Michael Aboud, Lloyd Curtis, Gregory Fusco> ;Therapeutic Advances in Drug Safety. 2018 Oct 29
• 72 citations
  Psychiatric Symptoms in Patients Receiving Dolutegravir.
  Anna Fettiplace, C. Stainsby, Alan Winston, Naomi Givens, Sarah Puccini, Vani Vannappagari, Ricky Hsu, Jennifer S Fusco, Romina Quercia, Michael Aboud, Lloyd Curtis> ;Journal of Acquired Immune Deficiency Syndromes. 2017 Apr 1
• 3 citations
  Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Pra...
  Philip Lackey, Anthony Mills, Felix Carpio, Ricky Hsu, Edwin DeJesus, Gerald Pierone, Cassidy Henegar, Jennifer S Fusco, Gregory Fusco, Mike Wohlfeiler> ;Clinical Drug Investigation. 2017 Jan 1
• 51 citations
  Telaprevir in the Treatment of Acute Hepatitis C Virus Infection in HIV-Infected Men
  Daniel S. Fierer, Douglas T. Dieterich, Michael P. Mullen, Andrea D. Branch, Alison J. Uriel, Damaris C. Carriero, Wouter O. van Seggelen, Rosanne M. Hijdra, David G. ...> ;Clinical Infectious Diseases. 2014 Mar 15
• 53 citations
  Rapid Progression to Decompensated Cirrhosis, Liver Transplant, and Death in HIV-Infected Men After Primary Hepatitis C Virus Infection
  Daniel S. Fierer, Douglas T. Dieterich, M. Isabel Fiel, Andrea D. Branch, Kristen M. Marks, Dahlene N. Fusco, Ricky Hsu, Davey M. Smith, Joshua Fierer> ;Clinical Infectious Diseases. 2013 Apr 1
• 902 citations
  The major genetic determinants of HIV-1 control affect HLA class I peptide presentation
  Florencia Pereyra, Xiaoming Jia, Paul J. McLaren, Amalio Telenti, de Bakker Pi, Bruce D. Walker, Stephan Ripke, Chanson J. Brumme, Sara L. Pulit, Mary Carrington, Carl...> ;Science. 2010 Dec 10
• 9 citations
  Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/...
  Lisa L. Ross, Richard Elion, Randall Lanier, Edwin DeJesus, Calvin J. Cohen, Robert R. Redfield, Joseph Gathe, Ricky Hsu, Linda Yau, Denise Paulsen, Belinda Ha> ;AIDS Research and Human Retroviruses. 2009 Jul 21
• 1 citations
  Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations:
  Ricky Hsu, Ernest R Lanier, Elizabeth G Rouse, Katrina L Oie, Keith A. Pappa, Lisa Ross> ;Antiviral Therapy. 2008 Jul 1
• 11 citations
  Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.
  Richard Elion, Calvin J. Cohen, Edwin DeJesus, Robert R. Redfield, Joseph Gathe, Ricky Hsu, Linda Yau, Lisa L. Ross, Belinda Ha, Randall Lanier, Trevor Scott> ;HIV Clinical Trials. 2006 Nov 1
• Role of Fluorine-18-Fluorodeoxyglucose in the Work-up of Febrile AIDS Patients. Experience with Dual Head Coincidence Imaging.
  Santiago, J.F., Jana, S., Gilbert, H.M., Salem, S., Bellman, P.C., Hsu, R.K., Naddaf, S., Abdel-Dayem, H.M.> ;Clin Positron Imaging. 1999 Nov
• Join now to see all

Journal Articles

• Rapid Progression to Decompensated Cirrhosis, Liver Transplantation, and Death in HIV-Infected Men after Primary HCV Infection.  
  Fierer, D, Dietrich, D, Fiel, M., Hsu, R, et al, Clinical Infectious Diseases
• The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation – The International HIV Controllers Study.  
  Walker, B., Hsu, R and multiple authors, et al, Journal of Antimicrobial Chemotherapy
• Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once a day abacavir/lamivudine/...  
  Ross, L., Hsu, R., Lanier, R., Dejesus, E., Cohen, C., Gathe, J., Hsu, R., et al, AIDS, July; 25(7):665-672
• Effect of Tenofovir Subtraction on HIV Plasma Viremia, CD4 and Resistance in a Patient with Baseline K65R and M184V Mutations.  
  Ross, L., Lanier, R., et al, Antiretroviral Therapy
• Once-Daily Abacavir/lamivudine/zidovudine plus tenofovir for the Treatment of HIV-1 Infection in Antiretroviral-naïve Subjects: a 48 Week Pilot Study.  
  Elion, R., Cohen, C., Dejesus, E., Gathe J., Hsu, R., et al, HIV Clinical Trials, 2006: 7(6): 324-333
• Trends in HIV Disease Management: Protease Inhibitors in Combination Therapy – A Grand Rounds Program.  
  Hsu, R, American Academy of HIV Medicine, Self-Directed HIV Medicine Study Guide, Volume 2
• 48 Week Analysis of Efficacy and Safety of QD Abacavir/Lamivudine/Zidovudine plus Tenofovir.  
  Cohen, C., Elion, R., Dejusus, E., Gathe, J., Hsu, R., et al, ICAAC, vol 45, page 264
• Selection of HIV RT Thymidine Analogue Mutations rather than K65R s the preferred Pathway in Patients with Virologic Failure on QD Trizivir and Tenofovir.  
  Elion, R., Ha, B., Dejusus, E., Cohen, C., Gathe, J., Hsu, R., et al, ICAAC, vol 45, page 271
• Do New Protease Inhibitors Offer Improved Sequencing Options?  
  Hsu, R. and Wainberg, M, JAIDS, Vol. 35, Supplement
• IgG Subclass Deficiency in HIV–1 Infection: A Potentially Unrecognized Secondary Immunodeficiency.  
  Hsu, R, JAIDS
• Sequencing or Success: A Case-Based Educational Program on Drug Resistance in HIV Therapy.  
  Gallant, J., Hsu, R., et al, Johns Hopkins School of Medicine and World Health CME
• Antiretroviral Drug Sequencing: Managing Resistance Across the Continuum of Care.  
  O’Brien, B., Cohan, G., Hsu, R, Discovery International
• The RRE of Human Immunodeficiency Virus Type 1 Contributes to Cell-Type-Specific Viral Tropism.  
  Dayton, E., Konings, D., Lim, S., Hsu, R., et al, Journal of Virology, May 1993, 2871-2878
• Join now to see all

Books/Book Chapters

• American Academy of HIV Medicine, Self-Directed HIV Medicine Study Guide. 
  Hsu, R

Abstracts/Posters

• NRTI Subtraction on HIV Plasma Viremia, CD4-Counts, and Resistance.
  Hsu, R., et al, 3rd International Workshop on HIV Persistence during Therapy, St Maarten, West Indies
• Fosamprenavir with Low-dose Ritonavir Once-Daily in HIV-Infected Subjects.
  Hsu, R. and Acosta, E, 7th Intl. Workshop Pharmacology, Lisbon, Portugal
• COL40263: A Pilot, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of a Once-Daily Regimen of Trizivir/Tenofovir Disoproxil Fumarate in Antiretrovir...
  Elion, R., Dejesus, E., Hsu, R, Abstract 53
• The Combination of Amprenavir with Low Dose Ritonavir in Salvage Regimens Overcomes Clinically Multiple-Drug Resistant Virus.
  Hsu, R. and Bellman, P, The XIII International AIDS Conference, Durban, South Africa
• Role of Fluorine-18-Fluorodeoxyglucose in the Work-up of Febrile AIDS Patients.
  Santiago, JF; Jana, S., Bellman, P., Hsu, R., Et al.,Co, M., Yano, S., Hsu, R., et al, Clinical Positron Imaging, 1999 Nov; 2(6):301-309
• Genomic Heterogeneity of DNA Repair: Role in Aging?
  Hanawalt, P., Gee, P., Hsu, R., Ho, L., and Kane, C, New York Academy of Science Conference Proceedings, 1991, 1-14
• Join now to see all

Lectures

• Long-term Complications of Antiretroviral Therapy. 
  Washington D.C, New York-NY, Dallas TX, Boston MA
• Nucleoside & Protease Inhibitor Sequencing. 
  National Advisory Board Speaker, GSK
• Resistance and Sequencing in Antiviral Therapy. 
  New York, Miami, and Houston
• Pharmacokinetic Enhancement of PI Based Treatment with HIV: Five Years Out. 
  Mount Sinai Hospital and Medical Center
• The Use of Amprenavir in Clinical Practice. 
• Pharmacokinetics. 
• Overcomes Clinically Multiple-Drug Resistant Virus. 
  XIII International AIDS Conference, Durban, South Africa
• Strategies in HIV Treatment: An Update, friends indeed. 
  New York, 1998, 2000
• HIV Care Guidelines for the Primary Care Physician. 
  UCLA Medical Center Conference
• HIV-1’s RRE Contributes to Cell-type Specific Viral Tropism. 
  National Institutes of Health
• The Correlation of DNA Repair with Transcriptional Modulation of the Plasminogen Gene Family. 
  Stanford University
• HIV Treatment Strategies in 2012. 
  Taipei, Taiwan, Shanghai & Beijing, China, Singapore, Singapore
• Review of a Clinical Study on Efficacy and Safety of maraviroc as a Part of a Combination Therapy in Treatment-Naïve Patients with CCR5-Tropic Virus. 
• Hepatic and Cardiovascular Considerations in the Aging HIV Patient. 
  European Virology Symposium, Paris, France
• Understanding the Selection of NRTI Backbones. 
  Multiple Locations
• Cardiovascular Complications in Patients with HIV – An Overview. 
  8th Annual European Virology Conference, Lisbon, Portugal
• Advances in HIV Therapeutics – from the Bench to the Clinic. 
  Credit Suisse Annual Biotechnology Conference, New York, NY
• The Role of CCR5 Antagonists and Tropism Testing in Clinical Practice. 
  Web-conference
• Understanding Fundamental Concepts of HIV Resistance and Testing. 
• Treatment Strategies and Management of the Newly Diagnosed Patient with HIV. 
  Johns Hopkins School of Medicine
• Treatment Strategies and Management of the Treatment Experienced Patient with HIV. 
  Johns Hopkins School of Medicine
• New and Emerging Therapies in Existing and Novel Classes: Clinical Trials Update. 
• Once Daily Protease Inhibitor HAART. 
  University of Cincinnati
• HIV Therapeutics in the Context of the Novel Antiretroviral Landscape. 
  Roche Pharmaceuticals
• Atazanavir in Clinical Practice. 
• Join now to see all